PPARG and Parkinson disease: Altogether, the results obtained from testing PPAR-α and γ agonists (such as fenofibrate, pioglitazone, resveratrol and rosiglitazone) in various neurological disorders support PPAR-α and PPAR-γ as potential novel targets for the therapeutic management of prevalent and debilitating conditions, such as Alzheimer’s and Parkinson’s disease.